CSF3 and infection: Therefore, according to National Comprehensive Cancer Network (NCCN) guidelines, prophylactic granulocyte colony-stimulating factor (G-CSF) is recommended for patients undergoing myelosuppressive chemotherapy with a high risk for FN (> 20%) and should be considered in patients with an intermediate risk for FN (10–20%; with ≥ 1 FN risk factor) to reduce the incidence of FN and infection-related complications [6, 11].